Dermatomyositis Treatment Market Expected To Reach $1.27 Billion By 2030 As Growth Accelerates At 6.8% CAGR
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Dermatomyositis Treatment Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The dermatomyositis treatment market size has grown strongly in recent years. It will grow from $0.91 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to autoimmune disease recognition, corticosteroid availability, rheumatology clinic expansion, hospital-based immunotherapy, supportive care development.
Projections for the dermatomyositis treatment market suggest robust expansion in the coming years, with an anticipated increase to $1.28 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.8%. This forecasted growth is largely driven by factors such as the broadening of biologic pipelines, advancements in precision immunology, the implementation of early autoimmune screening, the development of personalized treatment strategies, and the proliferation of specialized clinics. Key developments expected to shape this period include a heightened emphasis on biologic therapies, an increasing dependence on immunosuppressive medications, a wider adoption of multimodal treatment approaches, a greater focus on long-term physical therapy regimens, and enhanced capabilities for early diagnosis and continuous disease surveillance.
Download A Free Sample Report For Comprehensive Market Insights:
Dermatomyositis Treatment Market Development Factors: Which Trends Are Supporting Demand?
The future expansion of the dermatomyositis treatment market is anticipated to be driven by the rising incidence of autoimmune disorders. These conditions occur when the immune system erroneously targets and damages the body’s own healthy tissues. Increased rates of diagnosis, growing public awareness, and various environmental influences are fueling this rise in autoimmune disease prevalence, which in turn leads to a higher number of identified cases and reported incidents. Through the provision of specialized treatments that curb excessive immune activity and enhance patients’ well-being, dermatomyositis therapy plays a crucial role in combating this growing health challenge. As an example, the Autoimmune Institute—a nonprofit organization based in the United States—reported in February 2024 that autoimmune diseases affect between 5% and 10% of people in developed countries. Consequently, the upward trend in autoimmune disease cases is fueling the growth of the dermatomyositis treatment sector.
Dermatomyositis Treatment Market Segmentation: How Is The Market Structured Across Key Categories?
The dermatomyositis treatment market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatments, Immunosuppressants, Corticosteroids, Biologics, Physical Therapy
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Demographics: Age Group, Gender
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Pharmacological Treatments: Antimalarials, Antiviral Agents, Muscle Relaxants, Analgesics
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
4) By Biologics: Rituximab, Intravenous Immunoglobulin (IVIG), Tocilizumab, Abatacept
5) By Physical Therapy: Stretching Exercises, Strength Training, Aerobic Conditioning, Occupational Therapy
Dermatomyositis Treatment Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the dermatomyositis treatment market are dedicating efforts to creating advanced therapies, including selective complement-pathway inhibitors, in response to the growing need for treatments that are both more targeted and safer, and which avoid the broad immune suppression often associated with conventional options. These inhibitors work by specifically blocking elements of the complement cascade responsible for inflammation in dermatomyositis, delivering a more precise method compared to traditional immunosuppressive drugs that can indiscriminately impair immune activity. A notable case occurred in February 2025, when NovelMed Therapeutics Inc., a clinical-stage biotechnology firm based in the United States, secured clearance from the U.S. Food and Drug Administration (FDA) to launch a Phase II trial for Ruxoprubart (NM8074). This drug acts as a highly specific inhibitor of the alternative complement pathway by targeting Factor Bb. Through its action, Ruxoprubart has been demonstrated to regulate immune response by diminishing key inflammatory drivers while retaining vital immune roles such as opsonization and bacterial clearance, thereby potentially lowering risks in comparison to less selective complement blockers. The effectiveness and safety of this novel approach are currently being assessed in the context of dermatomyositis.
Dermatomyositis Treatment Market Competitive Landscape And Leading Companies
Major companies operating in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., Corbus Pharmaceuticals Holdings Inc.
Access The Complete Dermatomyositis Treatment Market Report:
Dermatomyositis Treatment Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the dermatomyositis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomyositis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
